HighTower Advisors’s Oruka Therapeutics ORKA Stock Holding History

HighTower Advisors’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-22	Closed	-$38K	–	1963
2015 Q2	$38K	Buy	22 +15	+214%	+$19.7K	﹤0.01%	1456
2015 Q1	$9K	Buy	+7	New	+$8.19K	﹤0.01%	1597
2014 Q4	–	Sell	-10	Closed	-$19K	–	1668
2014 Q3	$19K	Sell	10 -1	-9%	-$2.09K	﹤0.01%	1506
2014 Q2	$25K	Sell	11 -13	-54%	-$30.2K	﹤0.01%	1552
2014 Q1	$66K	Sell	24 -4	-14%	-$11.7K	﹤0.01%	1402
2013 Q4	$72K	Buy	28 +10	+56%	+$23.1K	﹤0.01%	1397
2013 Q3	$44K	Buy	+18	New	+$37.5K	﹤0.01%	1251

Other funds holding ORKA

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

HighTower Advisors's ORKA Position: Q3 2015 in Review

HighTower Advisors sold out of Oruka Therapeutics (ORKA) in Q3 2015, closing a stake of 22 shares — an estimated $38K sold.

HighTower Advisors first reported a position in ORKA in Q3 2013 and held it in 7 quarters. The position peaked at $72K in Q4 2013. 13 funds tracked by Wall St. Rank hold ORKA as of Q3 2015.

HighTower Advisors reported no remaining Oruka Therapeutics position as of Q3 2015 after selling out during the quarter.
HighTower Advisors sold 22 Oruka Therapeutics shares in Q3 2015, an estimated $38K.
HighTower Advisors first reported a position in Oruka Therapeutics in Q3 2013 and held it in 7 quarters.
HighTower Advisors's Oruka Therapeutics position peaked at $72K in Q4 2013.
13 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q3 2015.

Based on HighTower Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.